Sumitomo Mitsui Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $142 Billion
- Q3 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 3,149,399 shares of NTLA stock, worth $44 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
3,149,399
Previous 3,257,689
3.32%
Holding current value
$44 Million
Previous $72.9 Million
11.23%
% of portfolio
0.05%
Previous 0.05%
Shares
23 transactions
Others Institutions Holding NTLA
# of Institutions
313Shares Held
91.5MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$171 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$135 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$134 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$71.9 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$69.2 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.06B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...